Objectives: The aim of this study was to evaluate the effects of clinical pharmacists’ education and interventions on the appropriateness of dosage forms of drugs administered via the enteral feeding tubes (EFTs) in hospitalised patients in the neurology ward.Methods: This was a prospective, pre-post intervention study conducted among patients and neurologist team professionals in the neurology ward of a training and research hospital in Istanbul, Türkiye. The study was designed in two phases as a pre-education observation period (OP) and a post-education intervention period (IP), during which the clinical pharmacists provided the required recommendations. Medications evaluated in terms of EFT-related medication administration errors (EFTRMAE) during the hospitalisation and discharge of patients in OP and IP. The knowledge levels of the neurologist team regarding EFT medication administration were collected and evaluated with an online survey before and after the education program.Results: A total of 68 patients were included in the study, with 34 patients in the OP and 34 in the IP. During hospitalisation, EFTRMAEs were observed in 24 patients (70.6%) in the OP, whereas in the IP, EFTRMAEs were detected in 13 patients (38.2%) before clinical pharmacist interventions (p = 0.014). Throughout hospitalisation in the IP group, clinical pharmacists provided 25 interventions related to EFTRMAEs, of which 84% were accepted by physicians. However, only 11 of the accepted recommendations were fully implemented. Following these interventions, inappropriate drug administration via EFT remained in only 5 patients (14.7%) (p < 0.001). At hospital discharge, the EFTRMAE rate, which was 76.5% in the OP group, decreased to 23.5% in the IP group (p < 0.001). The neurologist team’s knowledge of EFT medication administration improved significantly following clinical pharmacist education, with the average number of correct responses increasing from 16.1 ± 4 before the education to 21.1 ± 2.1 afterward (p < 0.001).Conclusion: EFTRMAEs are frequently encountered in patients hospitalised in the neurology ward. Including clinical pharmacists in the healthcare team and the education program provided to physicians and nurses will increase the knowledge level of participants and the ability of physicians to prescribe appropriate dosage forms for administration via EFT.
Background: Pulmonary embolism (PE) poses significant morbidity and mortality risks, necessitating tailored anticoagulant therapy. Limited studies investigate the drug-related problems (DRPs) in PE. This study aims to evaluate the impact of clinical pharmacist (CP) interventions on drug-related problems (DRPs) and clinical outcomes in outpatients with PE. By addressing DRPs in this specific population, the study seeks to assess the role of CP-led interventions in enhancing patient safety and optimizing treatment outcomes. Methods: A randomized controlled trial was conducted on PE patients at a pulmonology outpatient clinic over the period of 15 January 2022 to January 2023. In this trial, the intervention group (IG) benefited from CP recommendations targeting DRPs, while the control group (CG) was observed without any additional interventions. Follow-ups were conducted at 90 and 180 days post-discharge. The study focused on DRPs, CP interventions, and patient outcomes. Data were systematically recorded and analyzed, adhering to ethical standards and employing the PCNE v9.1 classification system. Results: The study followed 50 PE patients, with 26 in the IG and 24 in the CG. DRPs, mostly in drug and dose selection, affected 84% of participants (3.34 DRPs/patient). In the IG, the CP made 76 recommendations (91.5%) for 83 DRPs at the prescribing physician level. Majority of these recommendations (94.7%) were accepted. At the 90-day follow-up, bleeding occurred in 16.6% of the CG, with none in the IG (odds ratio [OR] = 2.3, 95% confidence interval [CI]: 1.654–3.198, p = 0.046). As indicated by Cramér’s V (0.307), the effect size demonstrated a moderate association between the intervention and the absence of bleeding events in the IG. At the 180-day follow-up, bleeding was 33.3% in the CG and 16.6% in the IG (p = 0.443). Conclusions: PE patients experience common and frequent DRPs, especially in anticoagulation therapy. CP recommendations are widely accepted but need to be better implemented. No bleeding events were observed in the IG where a CP was involved at 90 days, unlike the CG. Including a CP in the PE treatment team seems to influence outcomes positively.
10 April 2025 in Journal of Pharmacy & Pharmaceutical Sciences
Objective: This study evaluated the use of stress ulcer prophylaxis (SUP), assessed the costs associated with inappropriate use, and highlighted the impact of clinical pharmacists on improving adherence to the SUP guidelines.Method: A prospective, non-randomized controlled study was carried out in two intensive care units (ICUs) of a training and research hospital between 1 June 2023 and 1 December 2023. Routine care services were provided for the observation group (OG) patients. In the guideline group (GG) patients, SUP management and routine care were performed according to ASHP guidelines. The physician and clinical pharmacist jointly evaluated the patients to determine the suitability of their SUP indications. Adherence rates to ASHP guidelines and the costs associated with nonadherence were evaluated.Results: A total of 196 patients were included in the study: 121 in the OG and 75 in the GG. A total of 54.6% of the patients were male, and the reason for hospitalization was mainly surgery (52.6%). SUP use was higher in OG (100%) than in GG (42.6%) (p < 0.001). The indication rate according to the ASHP guidelines was significantly higher in the GG group (100%) than in the OG group (54.5%) (p < 0.001). Dosage form adherence was significantly lower in the OG (0%) than in the GG (100%) (p < 0.001). The costs associated with proton pump inhibitor use for inappropriate indications and incorrect dosage forms were $60 versus $0 (p < 0.001) and $321 versus $0 (p < 0.001) in OG and GG, respectively. Overall, cost savings of $327 were achieved in the GG group.Conclusion: Inappropriate SUP use is common in the ICUs. Adequate adherence to guidelines and proactive involvement of clinical pharmacists may reduce inappropriate SUP in ICUs and the associated costs.
30 May 2023 in Ankara Universitesi Eczacilik Fakultesi Dergisi
Objective: Drug-related problems are a common health problem in hospitalized patients, affecting optimal patient outcomes. The aim of the study is to classify the drug-related problems detected by clinical pharmacy resident in hospitalized patients during their rotations and evaluate their interventions to the healthcare team. Material and Method: This is a retrospective study in which the drug-related problems of the patients hospitalized in the internal medicine wards between April and November 2018 were examined during the rotations of the clinical pharmacy resident. Patients’ demographics, prescribed medicine, laboratory findings were recorded. Drug-related problems are classified with the Pharmaceutical Care Network Europe Version 9.1 system. Result and Discussion: Ninety-two patients were included in the study. The median age of patients was 60.5 years and 59.8% of them were female. Most of the patients (63%) had three or more comorbidities. The most frequent comorbidities were hypertension (21.70%) and diabetes mellitus (10.64%). One hundred forty-seven drug-related problems were detected in 57 patients (62%). Potential drug-drug interactions (55.78%), errors in dosing timing instructions (9.52%), and inappropriate drug use according to guidelines (8.16%) were the most common causes of drug-related problems. The acceptance rate of interventions for resolving drug-related problems was 65%. The most common drug-related problems in this study were due to drug selection. The acceptance rate of recommendations for drug-related problems was lower than in the literature. However, this initial acceptance rate can be considered successful in a center where clinical pharmacy services have not been established.
Community pharmacies (CPs) are key healthcare providers, playing a significant role in optimizing drug therapy and preventing drug-related problems (DRPs). This study aims to assess the prevalence, characteristics, and related factors of DRPs in Turkish patients in the community pharmacy setting. A cross-sectional, prospective study was conducted between December 2023 and December 2024 in a community pharmacy. A total of 100 patients were included after excluding those with incomplete data. DRPs were evaluated using the PCNE V9.1 classification system, while Medication Adherence Report Scale (MARS) and Medication Regimen Complexity Index (MRCI) were used to assess adherence and regimen complexity. A total of 162 DRPs were identified, with an average of 1.6 DRPs per patient. DRPs were significantly associated with factors such as higher body mass index (p = 0.005), polypharmacy (p < 0.001), use of antidiabetic (p < 0.001) and antihypertensive medications (p = 0.005), and a higher number of comorbidities (p = 0.005). No significant relationship was observed between medication adherence and DRPs (p > 0.05). This study is among the first in Türkiye to evaluate DRPs in chronic disease management within a community pharmacy setting. The findings highlight the importance of clinical pharmacists in identifying and managing DRPs and suggest the need for integrated interventions in healthcare teams to improve patient outcomes and medication safety.